Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Arcellx, Inc. to Gilead Sciences, Inc. to assess the adequacy of the price and process involved in the transaction [1] Group 1: Proposed Transaction Details - Under the terms of the proposed sale, shareholders of Arcellx will receive $115.00 per share in cash, along with one contingent value right of $5.00 per share contingent on achieving certain milestones [1] - The investigation aims to determine whether the proposed consideration undervalues Arcellx and if the process leading to this valuation was adequate [1] Group 2: Legal Rights and Actions - Shareholders who believe the transaction undervalues the company are encouraged to discuss their legal rights with Kahn Swick & Foti, LLC [1] - The transaction is structured as a tender offer, indicating that timing may be critical for shareholders [1]